In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback